Analytik Jena enters Ultra-High Throughput Market

Access provided by Co-Marketing agreement with Illumina

09-Mar-2017 - Analytik Jena has entered a partnership with Illumina, Inc. headquartered in San Diego. In so doing Analytik Jena gains access to the growing genotyping market currently being served by Illumina’s technologies by offering a production scale solution to provide ultra-high throughput sample ...

Illumina Announces Corporate Reorganization

08-Jan-2008 - Illumina, Inc. announced that it has reorganized its operating structure to further leverage the synergies between its sequencing and genotyping businesses. Under the new structure, a newly created Life Sciences Business Unit will include all products and services related to the research market ...

GenoLogics Announces Bioinformatics Partnership with Illumina

25-Jun-2007 - GenoLogics announced that it has penned an agreement with Illumina, Inc. to become a technology partner and participant in IlluminaConnect, a bioinformatics software program established by Illumina to advance data integration and analysis among the life science community. GenoLogics will build ...

Integragen becomes first certified French service provider for Illumina GoldenGate and Infinium genotyping

20-Jun-2007 - Illumina, Inc. announced that IntegraGen SA has received Illumina Certified Service Provider (CSPro(TM)) certification for GoldenGate® and Infinium® genotyping technologies. The GoldenGate assay is Illumina's first array-based platform that combines high-sample throughput, high multiplexing, and ...

Illumina Signs Definitive Agreement to Acquire Solexa

15-Nov-2006 - Illumina, Inc. and Solexa, Inc. announced that they have entered into a definitive merger agreement under which Illumina will acquire Solexa in a stock-for-stock merger. Under the merger agreement, which was unanimously approved by the Boards of Directors of both companies, Solexa's stockholders ...

deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics

Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer

17-May-2006 - deCODE genetics and Illumina, Inc. announced the formation of a strategic alliance under which the companies plan to co-develop and commercialize DNA-based diagnostic tests in several major disease areas. The alliance will employ Illumina's platform for high-multiplex single-nucleotide ...

Illumina To Conduct Large-Scale Genotyping For Uk-Based Research Groups Studying Molecular Basis Of Prostate Cancer

13-Apr-2006 - llumina, Inc. announced that it has signed a genotyping services agreement to support prostate cancer researchers funded by Cancer Research UK. Under the terms of the agreement, valued at nearly $7 million, Illumina's service group will conduct whole-genome genotyping (>550,000 single nucleotide ...

PharmacoDesign Purchases Illumina Genotyping Solutions for Pharmacogenomics Research

Illumina to Gain Exclusive, Licensed Access to Biomarkers Discovered Through Disease Studies

27-Oct-2005 - Illumina, Inc. announced an agreement of sale with PharmacoDesign (PD) for a BeadStation system and whole-genome genotyping arrays and reagents for ongoing pharmacogenomics studies. PharmacoDesign will genotype various Korean populations with the aim of understanding genetic variation and ...

Illumina and Glaxosmithkline Sign Agreement For Large-Scale Genotyping Studies

26-Sep-2005 - Illumina, Inc. announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium(TM) assays to conduct genetic studies for ...

Illumina To Conduct Large-Scale Genotyping Study for North American Rheumatoid Arthritis Consortium

20-Sep-2004 - Illumina, Inc. announced that it has signed a commercial agreement to conduct an extensive, two-phase genotyping study for the North American Rheumatoid Arthritis Consortium (NARAC) to identify genes associated with this complex and debilitating disease. The NARAC study will be led by Peter K. ...